PHGE — BiomX Inc.

NYSE · Health Care · Biotechnology · CIK 1739174 ·
Last close
$1.62
Market Cap
$16.38M
52W High
$8.10
52W Low
$0.36
ADV30
11,317,247
Next earnings
2026-08-12
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -1,296,000 -19,140,000 3,251,000 1,168,000 4,132,000
Sep 2025 0 -8,536,000 -9,166,000 26,168,000 6,923,000 15,682,000
Jun 2025 0 -7,433,000 -6,037,000 38,050,000 14,046,000 18,890,000
Mar 2025 0 -7,756,000 -7,659,000 45,654,000 20,116,000 21,155,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-28,293,000
Investing CF
$106,000
Financing CF
$11,540,000
CapEx
$-21,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-9.50
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-203,559,000
Inventory
Receivables
$280,000
ST Investments
EBIT TTM
$-38,425,000
Pretax Income TTM
$-37,366,000
Interest Exp TTM
$-1,059,000
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 0 -35,551,000 -17,727,000 43,233,000 19,085,000 -36,979,000
Dec 2023 0 -25,348,000 -26,169,000 25,029,000 21,948,000 -21,286,000
Dec 2022 0 -27,219,000 -28,317,000 45,531,000 24,492,000 -29,092,000
Dec 2021 0 -35,462,000 -36,226,000 77,990,000 30,455,000 -27,573,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-6.01

Peers — same industry

TickerNameMarket CapLastDaily %
INAB IN8BIO, INC. $16.64M $1.69
PASG Passage BIO, Inc. $17.80M $5.55
ZEOX Zeo ScientifiX, Inc. $14.78M $1.90
GNTA Genenta Science S.p.A. $14.09M $0.60
CRIS CURIS INC $19.26M $0.49

News headlines (Yahoo Finance, 1h cache)

BiomX’s Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand
2026-05-06 20:15 · Yahoo
Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems
2026-04-16 20:30 · Yahoo
BiomX Accelerates Defense Technology Buildout with DFSL Acquisition
2026-04-13 13:20 · Yahoo
BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications
2026-04-10 12:30 · Yahoo
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
2026-03-31 14:48 · Yahoo
BiomX Adds Former Mossad Deputy to Advisory Board
2026-03-30 13:28 · Yahoo
BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
2026-03-27 20:30 · Yahoo
BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations
2026-03-26 12:48 · Yahoo
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets
2026-03-25 17:10 · Yahoo
BiomX CEO Issues Letter to Stockholders
2026-03-19 13:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.